- April 20, 2018 17:35 (CEST)Regulatory
Cyxone announced today that the date of the company's Annual General Meeting (AGM) will be changed to June 5, 2018 due to the intensification of the work related to the financing of the company's drug candidate Rabeximod.
- April 10, 2018 11:43 (CEST)Regulatory
Cyxone announced today that the company’s immunomodulating cyclotide drug, T20K, and its development potential have been recognized in the renowned journal International Journal of Peptide research and Therapeutics. The published scientific article describes the distinct properties of the natural plant protein cyclotides and its demonstrated potential as promising therapeutics in immunopharmacological applications, for example as a treatment for autoimmune diseases.
- March 27, 2018 14:24 (CEST)Regulatory
Cyxone announced today that the first phase of their cyclotide pilot study into inflammatory bowel disease (IBD) has been concluded as planned. The study was conducted after an inquiry by a pharmaceutical company that had observed Cyxone’s research for its T20K in multiple sclerosis (MS). Interest was shown for the discovery of the cyclotide’s ability to inhibit a key factor for inflammatory diseases, IL2, and it also appears to accumulate in the intestine and spleen, the organs considered to be involved in IBD. Results from the first phase of the study show a positive effect on the lymph nodes, indicating that the cyclotide reduces T-cell activity, which is considered to be a contributing factor to the uncontrolled inflammation that occurs in IBD.
- February 16, 2018 08:50 (CET)
- January 31, 2018 10:42 (CET)
In response to interest from drug companies, Cyxone is to review whether cyclotides are effective against inflammatory bowel disease (IBD). The study was planned by the Medical University of Vienna and is now underway.
- December 11, 2017 14:00 (CET)
Today, December 11, 2017, Cyxone AB (publ.) held an extraordinary general meeting. Below is an overview of the motions decided upon. All motions were taken with the necessary majority of votes.
- December 6, 2017 08:30 (CET)
- November 23, 2017 08:55 (CET)
Shareholders in Cyxone AB (publ.), 559020-5471, are hereby invited to an extraordinary general meeting at Setterwalls Advokatbyrå AB, Stortorget 23, in Malmö, on Monday, December 11, 2017 at 10:00AM.
- November 23, 2017 08:50 (CET)
As previously announced, Cyxone acquired Rabeximod from OxyPharma in June 2017. Rabeximod has undergone Phase 2 trials in patients with moderate to severe rheumatoid arthritis in which significant improvements in the condition's symptoms were discovered four weeks after the completion of the formal (12 week) trial period.
Existing Rabeximod can be used in Cyxone's planned Phase 2b study in patients with rheumatoid arthritisNovember 6, 2017 16:54 (CET)
Cyxone has analysed the Rabeximod that was previously manufactured by OxyPharma for clinical trials at Syntagon AB. Results show that the existing substance, despite having been stored for several years, can be used in Cyxone's upcoming Phase 2b study in patients with rheumatoid arthritis.